Hyperparathyroidism and dialysis vintage
- PMID: 11076105
Hyperparathyroidism and dialysis vintage
Abstract
Background: Secondary hyperparathyroidism and its effects on bone and viscera are among the most important complications of end-stage renal disease. Despite its ubiquity, little is known about the treated natural history of the disorder.
Methods: We assembled a cohort of 310 patients with endstage renal disease on hemodialysis who were participants in one of four clinical trials of the phosphate binder sevelamer. Baseline parathyroid hormone levels were collected, and the relation between dialysis vintage and other clinical variables with parathyroid hormone were described.
Results: There was a direct relation between dialysis vintage and the severity of hyperparathyroidism. Other variables that were significantly associated with PTH on univariate analysis included age, African American race, Kt/V, and the serum concentrations of calcium, phosphate, and bicarbonate. Multivariable linear regression analysis yielded three significant predictors of PTH: calcium, phosphorus, and vintage (5.8% (4.0-7.5%) expected increase in PTH per year of vintage). The model R2 was 0.22.
Conclusion: Dialysis vintage is a key determinant of the severity of secondary hyperparathyroidism. Vintage and certain laboratory variables should be considered in the evaluation of therapies aimed at modifying the treated natural history of this disorder.
Similar articles
-
1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.Dan Med Bull. 2008 Nov;55(4):186-210. Dan Med Bull. 2008. PMID: 19232159 Review.
-
Oral paricalcitol for the treatment of secondary hyperparathyroidism in patients on hemodialysis or peritoneal dialysis.Am J Nephrol. 2008;28(1):97-106. doi: 10.1159/000109398. Epub 2007 Oct 3. Am J Nephrol. 2008. PMID: 17914251 Clinical Trial.
-
RenaGel efficacy in severe secondary hyperparathyroidism.Nefrologia. 2002;22(5):448-55. Nefrologia. 2002. PMID: 12497746
-
Race and sex: predictors of the severity of hyperparathyroidism in peritoneal dialysis patients.Nephrology (Carlton). 2006 Feb;11(1):15-20. doi: 10.1111/j.1440-1797.2006.00531.x. Nephrology (Carlton). 2006. PMID: 16509926
-
[Complications of dialysis].Nihon Naika Gakkai Zasshi. 1995 Sep 10;84(9):1532-7. Nihon Naika Gakkai Zasshi. 1995. PMID: 8537763 Review. Japanese. No abstract available.
Cited by
-
Cost-effectiveness analysis of cinacalcet for haemodialysis patients with moderate-to-severe secondary hyperparathyroidism in China: evaluation based on the EVOLVE trial.BMJ Open. 2020 Aug 4;10(8):e034123. doi: 10.1136/bmjopen-2019-034123. BMJ Open. 2020. PMID: 32753447 Free PMC article.
-
Medication burden in CKD-5D: impact of dialysis modality and setting.Clin Kidney J. 2014 Dec;7(6):557-61. doi: 10.1093/ckj/sfu091. Epub 2014 Sep 11. Clin Kidney J. 2014. PMID: 25859372 Free PMC article.
-
Mortality in Hemodialysis Patients with COVID-19, the Effect of Paricalcitol or Calcimimetics.Nutrients. 2021 Jul 26;13(8):2559. doi: 10.3390/nu13082559. Nutrients. 2021. PMID: 34444716 Free PMC article.
-
Confounded complexity: vitamin d, parathyroid hormone, and metabolic syndrome in peritoneal dialysis.Perit Dial Int. 2014 Jun;34(4):333-7. doi: 10.3747/Pdi.2014.00005. Perit Dial Int. 2014. PMID: 24991048 Free PMC article. No abstract available.
-
Are oxyphil cells responsible for the ineffectiveness of cinacalcet hydrochloride in haemodialysis patients?Clin Kidney J. 2018 Jul 23;12(3):433-436. doi: 10.1093/ckj/sfy062. eCollection 2019 Jun. Clin Kidney J. 2018. PMID: 31198545 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical